Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

Committee for Human Medicinal Products (CHMP) recommended approval of five novel medicines at its September meeting ...

BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...

Basilea Pharmaceutica (SIX: BSLN) announced that the Biomedical Advanced Research and Development Authority (BARDA), part of ...

Sanofi has reported positive results from its Phase III HERCULES trial of tolebrutinib for non-relapsing secondary ...

Edgewise Therapeutics has reported positive top-line results for its HCM treatment candidate, EDG-7500, boosting shares by ...

The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

The US Food and Drug Administration yesterday approved a new indication for Rybrevant (amivantamab-vmjw), from Johnson & ...

The Israeli Ministry of Health (IL MOH) has approved Tevimbra (tislelizumab) as monotherapy for the treatment of adult ...

Eurofins Genomics US has opened a new oligonucleotide manufacturing facility, expanding its capacity to meet growing global demand for GMP-grade and research use oligonucleotides. The facility will ...

Aligos Therapeutics (Nasdaq: ALGS) has announced positive top-line results from the Phase IIa HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction ...

GC Therapeutics (GCTx) has launched with its TFome platform, developed by scientists at Harvard and the Wyss Institute, ...